Teriflunomide in patients with multiple sclerosis

Abstract

The article discusses the prospects for the use of the new drug teriflunomide for the treatment of patients with relapsing-remitting multiple sclerosis. By now, phase II and III clinical trials are completed which demonstrated good tolerability, efficacy and relative safety of teriflunomide. The TEMSO and TOWER trials showed a decrease in the incidence of relapse which was a reason for hospitalization (by 59 and 37%, respectively), as well as in the incidence of exacerbations requiring treatment with corticosteroids (by 34 and 36%, respectively).

Keywords

• рассеянный склероз
• препараты
• изменяющие течение рассеянного склероза
• терифлуномид
• multiple sclerosis
• multiple sclerosis sease-modifying medications
• teriflunomide